Relationships between lymph node metastasis and expression of CD31, D2-40, and vascular endothelial growth factors A and C in papillary thyroid cancer

Clinical and Experimental Otorhinolaryngology

Volumn 5, Issue 3, 2012, Pages 150-155

  Lee, Sang Hyuk ^a   Lee, Sung Jin ^a   Jin, Sung Min ^a   Lee, No Hee ^a   Kim, Dong Hoon ^a   Chae, Seung Wan ^a   Sohn, Jin Hee ^a   Kim, Won Serk ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Lymph node; Metastasis; Papillary carcinoma; Thyroid; VEGF A; VEGF C

Indexed keywords

EID: 84930473285     PISSN: 19768710     EISSN: 20050720     Source Type: Journal    
DOI: 10.3342/ceo.2012.5.3.150     Document Type: Article

References (34)

1. Tian X, Cong M, Zhou W, Zhu J, Liu Q. Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer. J Int Med Res. 2008 Jul-Aug;36(4):699-703.
2. Noguchi S, Murakami N, Yamashita H, Toda M, Kawamoto H. Papillary thyroid carcinoma: modified radical neck dissection improves prognosis. Arch Surg. 1998 Mar;133(3):276-80.
3. Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol. 2007 Aug;88(4):271-7.
4. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992 Feb;13(1):18-32.
5. Lohela M, Helotera H, Haiko P, Dumont DJ, Alitalo K. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues. Am J Pathol. 2008 Dec;173(6):1891-901.
6. Wang SL, Li SH, Chen WT, Chai CY. Expression of D2-40 in adjunct diagnosis of papillary thyroid carcinoma. APMIS. 2007 Aug;115(8): 906-10.
7. DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, Wexler RS, et al. Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol. 1997 Sep;151(3):671-7.
8. Lennard CM, Patel A, Wilson J, Reinhardt B, Tuman C, Fenton C, et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery. 2001 May;129(5):552-8.
9. de la Torre NG, Buley I, Wass JA, Turner HE. Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocr Relat Cancer. 2006 Sep;13(3):931-44.
10. Chung MK, Kim JH, Ko YH, Son YI. Correlation of lymphatic vessel density and vascular endothelial growth factor with nodal metastasis in papillary thyroid microcarcinoma. Head Neck. 2011 Aug 18 [Epub]. http://dx.doi.org/10.1002/hed.21822.
11. Bono P, Wasenius VM, Heikkila P, Lundin J, Jackson DG, Joensuu H. High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin Cancer Res. 2004 Nov;10(21): 7144-9.
12. Fox SB. Tumour angiogenesis and prognosis. Histopathology. 1997 Mar;30(3):294-301.
13. Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res. 2001 Mar;7(3):462-8.
14. Mohammed RA, Green A, El-Shikh S, Paish EC, Ellis IO, Martin SG. Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer. 2007 Apr;96(7):1092-100.
15. Sahni D, Robson A, Orchard G, Szydlo R, Evans AV, Russell-Jones R. The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status. J Clin Pathol. 2005 Jul;58(7):715-21.
16. Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol. 2000 Sep;166(3):475-80.
17. Turner HE, Harris AL, Melmed S, Wass JA. Angiogenesis in endocrine tumors. Endocr Rev. 2003 Oct;24(5):600-32.
18. Bunone G, Vigneri P, Mariani L, Buto S, Collini P, Pilotti S, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol. 1999 Dec;155(6):1967-76.
19. Kilicarslan AB, Ogus M, Arici C, Pestereli HE, Cakir M, Karpuzoglu G. Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas. APMIS. 2003 Mar;111(3):439-43.
20. Herrmann G, Schumm-Draeger PM, Muller C, Atai E, Wenzel B, Fabian T, et al. T lymphocytes, CD68-positive cells and vascularisation in thyroid carcinomas. J Cancer Res Clin Oncol. 1994 Nov;120(11):651-6.
21. Akslen LA, Livolsi VA. Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance. Hum Pathol. 2000 Apr; 31(4):439-42.
22. Tanaka K, Sonoo H, Kurebayashi J, Nomura T, Ohkubo S, Yamamoto Y, et al. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma. Clin Cancer Res. 2002 May; 8(5):1125-31.
23. Fontanini G, Vignati S, Pacini F, Pollina L, Basolo F. Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma. Mod Pathol. 1996 Jun;9(6): 636-41.
24. Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol. 2003 Jun;162(6):1951-60.
25. Franchi A, Gallo O, Massi D, Baroni G, Santucci M. Tumor lymphangiogenesis in head and neck squamous cell carcinoma: a morphometric study with clinical correlations. Cancer. 2004 Sep;101(5): 973-8.
26. Birner P, Obermair A, Schindl M, Kowalski H, Breitenecker G, Oberhuber G. Selective immunohistochemical staining of blood and lymphatic vessels reveals independent prognostic influence of blood and lymphatic vessel invasion in early-stage cervical cancer. Clin Cancer Res. 2001 Jan;7(1):93-7.
27. Dhar DK, Kubota H, Kotoh T, Tabara H, Watanabe R, Tachibana M, et al. Tumor vascularity predicts recurrence in differentiated thyroid carcinoma. Am J Surg. 1998 Nov;176(5):442-7.
28. He Y, Karpanen T, Alitalo K. Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta. 2004 Mar;1654(1):3-12.
29. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001 Feb;20(4):672-82.
30. Beasley NJ, Prevo R, Banerji S, Leek RD, Moore J, van Trappen P, et al. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res. 2002 Mar;62(5):1315-20.
31. Siironen P, Ristimaki A, Narko K, Nordling S, Louhimo J, Andersson S, et al. VEGF-C and COX-2 expression in papillary thyroid cancer. Endocr Relat Cancer. 2006 Jun;13(2):465-73.
32. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999 Jan;13(1): 9-22.
33. Garcia EA, Simoes K, Wakamatsu A, Ressio RA, Alves VA, Longatto-Filho A, et al. Lymphatic vessel density and VEGF-C expression are significantly different among benign and malignant thyroid lesions. Endocr Pathol. 2010 Jun;21(2):101-7.
34. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science. 2002 Jun;296(5574):1883-6.